|Bid||125.00 x 900|
|Ask||150.00 x 800|
|Day's Range||128.62 - 129.62|
|52 Week Range||81.56 - 130.00|
|Beta (3Y Monthly)||1.41|
|PE Ratio (TTM)||50.10|
|Earnings Date||Feb 26, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||126.20|
Medtronic (MDT) is expected to maintain a decent market share in the core pacing backed by the continued uptake of Micra Transcatheter Pacing System in Q3.
DexCom (DXCM) expects to gain from strong demand for the G6 sensors. These sensors are likely to rake in huge profits during the fourth quarter of 2018.
Canopy Growth (CGC) is expected to benefit from solid top-line contribution from the Canadian medical cannabis market and the legalization of the recreational use of cannabis in Q3.
Doctella Facilitates Pre- and Post-hospital Care at Home with Customizable, Interactive CarePrograms™ That Utilize Patient-reported and Physiological Data
Masimo Corp NASDAQ/NGS:MASIView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for MASI with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MASI. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding MASI totaled $1.37 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Today we'll evaluate Masimo Corporation (NASDAQ:MASI) to Read More...
NEW YORK, Feb. 06, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
Medical Instruments companies are likely to gain from strong performance in emerging economies and modernization of 510 (k)-clearance pathway by the FDA in Q4.
Cardinal Health (CAH) likely to gain from solid Pharmaceutical revenues in fiscal Q2; medical-gloves sub-segment likely to be soft.
Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Masimo MightySat Rx, Now Also Indicated for Use at Home, is the First Fingertip Pulse Oximeter with SET® and the First to Measure Respiration Rate
Iris Device Management System Facilitates Remote Management of Masimo Point-of-care Devices Throughout the Hospital
If you're worried about recent guidance revisions downward, here are three top stocks from the healthcare sector that recently raised their outlook.
Joe Kiani has been the CEO of Masimo Corporation (NASDAQ:MASI) since 1989. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we'll consider growth that Read More...
Wall Street rallied for the fourth successive day owing to positive developments on the trade front and Fed Chair???s indication of maintaining caution on further interest rate hikes.
Masimo (MASI) issues guidance for 2019. It anticipates witnessing strong contribution from its core product revenue segment.
NEW YORK, NY / ACCESSWIRE / January 10, 2019 / U.S. markets rose for the fourth consecutive session on Wednesday as minutes released from the Federal Reserve's meeting in December showed the Fed would be “patient” when it came to interest rate hikes. The Dow Jones Industrial Average gained 0.39 percent to close at 23,879.12, while the S&P 500 Index rose 0.41 percent to settle at 2,584.96. The Nasdaq Composite Index surged 0.87 percent to close at 6,957.08.
Complete fourth quarter and full year 2018 financial results will be announced on Tuesday, February 26, 2019
Masimo (MASI), a global medical technology developer and manufacturer of innovative noninvasive patient monitoring technologies, announced today that Julie A. Shimer, Ph.D. has been appointed to Masimo’s Board of Directors. Dr. Shimer is currently a private investor and has over 30 years of product development experience. Dr. Shimer was President and Chief Executive Officer of Welch Allyn, from March 2007 to April 2012.